{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T05:24:43Z","timestamp":1730870683711,"version":"3.28.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00104-021-01454-1","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T10:05:42Z","timestamp":1625565942000},"page":"803-808","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodale Therapie ampull\u00e4rer Karzinome","Multimodal treatment of periampullary carcinoma"],"prefix":"10.1007","volume":"92","author":[{"given":"Timm M.","family":"Rei\u00dfig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"1454_CR1","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/bjs.10563","volume":"104","author":"A Acharya","year":"2017","unstructured":"Acharya\u00a0A, Markar\u00a0SR, Sodergren\u00a0MH et al (2017) Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma: adjuvant therapy after surgery for periampullary adenocarcinoma. Br J Surg 104:814\u2013822","journal-title":"Br J Surg"},{"key":"1454_CR2","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ijrobp.2006.04.018","volume":"66","author":"S Bhatia","year":"2006","unstructured":"Bhatia\u00a0S, Miller\u00a0RC, Haddock\u00a0MG et\u00a0al (2006) Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 66:514\u2013519","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1454_CR3","volume-title":"WHO classification of tumours of the digestive system","author":"FT Bosman","year":"2010","unstructured":"Bosman\u00a0FT (2010) WHO classification of tumours of the digestive system. WHO, Lyon"},{"key":"1454_CR4","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ejso.2015.01.010","volume":"41","author":"O Colussi","year":"2015","unstructured":"Colussi\u00a0O, Voron\u00a0T, Pozet\u00a0A et\u00a0al (2015) Prognostic score for recurrence after Whipple\u2019s pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort. Eur J Surg Oncol 41:520\u2013526","journal-title":"Eur J Surg Oncol"},{"key":"1454_CR5","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamasurg.2019.1170","volume":"154","author":"BL Ecker","year":"2019","unstructured":"Ecker\u00a0BL, Vollmer\u00a0CM, Behrman\u00a0SW et al (2019) Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. JAMA Surg 154:706","journal-title":"JAMA Surg"},{"key":"1454_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.celrep.2015.12.005","volume":"14","author":"MC Gingras","year":"2016","unstructured":"Gingras\u00a0MC, Covington\u00a0KR, Chang\u00a0DK et\u00a0al (2016) Ampullary cancers harbor ELF3 tumor suppressor gene mutations and exhibit frequent WNT dysregulation. Cell Rep 14:907\u2013919","journal-title":"Cell Rep"},{"key":"1454_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan\u00a0T, Hammel\u00a0P, Reni\u00a0M et al (2019) Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N\u00a0Engl J Med 381:317\u2013327","journal-title":"N Engl J Med"},{"key":"1454_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/cncr.30445","volume":"123","author":"P Gulhati","year":"2017","unstructured":"Gulhati\u00a0P, Raghav\u00a0K, Shroff\u00a0RT et al (2017) Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: a single-center, open-label, phase 2\u00a0study. Cancer 123:1011\u20131017","journal-title":"Cancer"},{"key":"1454_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26435","author":"M Guo","year":"2021","unstructured":"Guo\u00a0M, Beal\u00a0EW, Miller\u00a0ED et al (2021) Neoadjuvant therapy versus surgery first for ampullary carcinoma: a propensity score-matched analysis of the NCDB. J\u00a0Surg Oncol. https:\/\/doi.org\/10.1002\/jso.26435","journal-title":"J Surg Oncol"},{"key":"1454_CR10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ijrobp.2007.07.2327","volume":"70","author":"S Krishnan","year":"2008","unstructured":"Krishnan\u00a0S, Rana\u00a0V, Evans\u00a0DB et\u00a0al (2008) Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys 70:735\u2013743","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1454_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/SLA.0000000000001182","volume":"262","author":"J Kwon","year":"2015","unstructured":"Kwon\u00a0J, Kim\u00a0BH, Kim\u00a0K et al (2015) Survival benefit of adjuvant chemoradiotherapy in patients with ampulla of Vater cancer: a systematic review and meta-analysis. Ann Surg 262:47\u201352","journal-title":"Ann Surg"},{"key":"1454_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2019.37.4_suppl.318","volume":"37","author":"S Leonard-Murali","year":"2019","unstructured":"Leonard-Murali\u00a0S, Shah\u00a0RA, Ivanics\u00a0T et al (2019) Neoadjuvant chemotherapy versus upfront resection in ampullary adenocarcinoma stratified by stage: a retrospective analysis using the national cancer database. J\u00a0Clin Oncol 37:318\u2013318","journal-title":"J Clin Oncol"},{"key":"1454_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00323","author":"S Lundgren","year":"2019","unstructured":"Lundgren\u00a0S, Hau\u00a0SO, Elebro\u00a0J et\u00a0al (2019) Mutational landscape in resected periampullary adenocarcinoma: relationship with morphology and clinical outcome. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00323","journal-title":"JCO Precis Oncol"},{"key":"1454_CR14","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/SLA.0000000000003177","volume":"272","author":"AL Moekotte","year":"2020","unstructured":"Moekotte\u00a0AL, Lof\u00a0S, Van Roessel\u00a0S et\u00a0al (2020) Histopathologic predictors of survival and recurrence in resected ampullary adenocarcinoma: international multicenter cohort study. Ann Surg 272:1086\u20131093","journal-title":"Ann Surg"},{"key":"1454_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/bjs.11555","volume":"107","author":"AL Moekotte","year":"2020","unstructured":"Moekotte\u00a0AL, Malleo\u00a0G, van Roessel\u00a0S et al (2020) Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study. Br J Surg 107:1171\u20131182","journal-title":"Br J Surg"},{"key":"1454_CR16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1097\/SLA.0b013e318190c53e","volume":"248","author":"MJ Morak","year":"2008","unstructured":"Morak\u00a0MJ, van der Gaast\u00a0A, Incrocci\u00a0L et al (2008) Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a\u00a0prospective randomized controlled trial. Ann Surg 248:1031\u20131041","journal-title":"Ann Surg"},{"key":"1454_CR17","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1748-717X-6-126","volume":"6","author":"AK Narang","year":"2011","unstructured":"Narang\u00a0AK, Miller\u00a0RC, Hsu\u00a0CC et al (2011) Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol 6:126","journal-title":"Radiat Oncol"},{"key":"1454_CR18","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","volume":"308","author":"JP Neoptolemos","year":"2012","unstructured":"Neoptolemos\u00a0JP, Moore\u00a0MJ, Cox\u00a0TF et al (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC\u20113 periampullary cancer randomized trial. JAMA 308:147\u2013156","journal-title":"JAMA"},{"key":"1454_CR19","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","volume":"27","author":"MJ Overman","year":"2009","unstructured":"Overman\u00a0MJ, Varadhachary\u00a0GR, Kopetz\u00a0S et\u00a0al (2009) Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J\u00a0Clin Oncol 27:2598\u20132603","journal-title":"J Clin Oncol"},{"key":"1454_CR20","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1245\/s10434-011-2117-1","volume":"19","author":"M Palta","year":"2012","unstructured":"Palta\u00a0M, Patel\u00a0P, Broadwater\u00a0G et\u00a0al (2012) Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol 19:1535\u20131540","journal-title":"Ann Surg Oncol"},{"key":"1454_CR21","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1097\/MPA.0000000000000112","volume":"43","author":"P-E Robert","year":"2014","unstructured":"Robert\u00a0P\u2011E, Leux\u00a0C, Ouaissi\u00a0M et al (2014) Predictors of long-term survival following resection for ampullary carcinoma: a\u00a0large retrospective French multicentric study. Pancreas 43:692\u2013697","journal-title":"Pancreas"},{"key":"1454_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2021.03.228","author":"S van Roessel","year":"2021","unstructured":"van Roessel\u00a0S, Soer\u00a0EC, Daamen\u00a0LA et\u00a0al (2021) Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: a multicentre retrospective cohort study. Eur J Surg Oncol. https:\/\/doi.org\/10.1016\/j.ejso.2021.03.228","journal-title":"Eur J Surg Oncol"},{"key":"1454_CR23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne\u00a0E, Suker\u00a0M, Groothuis\u00a0K et\u00a0al (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J\u00a0Clin Oncol 38:1763\u20131773","journal-title":"J Clin Oncol"},{"key":"1454_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1471-2407-8-170","volume":"8","author":"A Westgaard","year":"2008","unstructured":"Westgaard\u00a0A, Tafjord\u00a0S, Farstad\u00a0IN et\u00a0al (2008) Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer 8:170","journal-title":"BMC Cancer"},{"key":"1454_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamasurg.2016.3466","volume":"152","author":"JL Williams","year":"2017","unstructured":"Williams\u00a0JL, Chan\u00a0CK, Toste\u00a0PA et\u00a0al (2017) Association of histopathologic phenotype of periampullary adenocarcinomas with survival. JAMA Surg 152:82","journal-title":"JAMA Surg"},{"key":"1454_CR26","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/cncr.31951","volume":"125","author":"W Wong","year":"2019","unstructured":"Wong\u00a0W, Lowery\u00a0MA, Berger\u00a0MF et\u00a0al (2019) Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer 125:1441\u20131448","journal-title":"Cancer"},{"key":"1454_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","volume":"29","author":"S Yachida","year":"2016","unstructured":"Yachida\u00a0S, Wood\u00a0LD, Suzuki\u00a0M et\u00a0al (2016) Genomic sequencing identifies ELF3 as a\u00a0driver of ampullary carcinoma. Cancer Cell 29:229\u2013240","journal-title":"Cancer Cell"},{"key":"1454_CR28","doi-asserted-by":"publisher","first-page":"12676","DOI":"10.1038\/s41598-019-49179-w","volume":"9","author":"C Zimmermann","year":"2019","unstructured":"Zimmermann\u00a0C, Wolk\u00a0S, Aust\u00a0DE et\u00a0al (2019) The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep 9:12676","journal-title":"Sci Rep"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-021-01454-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-021-01454-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-021-01454-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T11:10:16Z","timestamp":1730805016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-021-01454-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1007\/s00104-021-01454-1","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"type":"print","value":"0009-4722"},{"type":"electronic","value":"1433-0385"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"1 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.T.\u00a0Siveke weist auf folgende Beziehungen hin: Erhalt von Forschungsf\u00f6rderung von Bristol-Myers Squibb, Celgene, Roche; Vortrags- und Beratungshonorare von AstraZeneca, Aurikamed, Baxalta, Bayer, Bristol-Myers Squibb, Celgene, Falk Foundation, iomedico, Immunocore, Novartis, Roche, Servier, Shire; Firmenanteile an iTheranostics und Pharma15 (<\u202f3\u202f%); Mitglied des Aufsichtsrats von Pharma15. T.M.\u00a0Rei\u00dfig gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}